Search

Byron Hua Kwan

from Seattle, WA
Age ~37
Get Report
Also known as:
Byron H Kwan
Phone and address:
1718 NW 60Th St, Seattle, WA 98107
Connected to:
Adrienne H Kwan, 36Ah A Kwan, 54Ann C Kwan, 35Bob K Kwan, 85Caren D Kwan, 38Cheston E Kwan, 43Chiman Kwan, 60Cho Y Kwan, 67Chui Kwan, 62Chung Kwan, 57

Byron Kwan Phones & Addresses

  • 1718 NW 60Th St, Seattle, WA 98107
  • Bothell, WA
  • Irvine, CA
  • Cambridge, MA
  • Allston, MA
  • Los Angeles, CA
  • Chino Hills, CA

Work

Company: Seattle genetics Dec 2019 Position: Senior scientist

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Massachusetts Institute of Technology 2010 to 2015 Specialities: Biological Engineering

Skills

Cell Culture • Flow Cytometry • Matlab • Tumor Immunology • Fluorescence Microscopy • Western Blotting • Confocal Microscopy • Cancer Immunotherapy • Protein Engineering • Biological Engineering • Mouse Models • Pcr • Microsoft Office • Antibodies • Fplc • Cloning • Mouse Handling • Protein Expression • Protein Purification • Protein Production • Molecular Biology • Gel Electrophoresis • Immunohistochemistry • Immunofluorescence • Flowjo • Imagej • Graphpad Prism

Languages

English

Industries

Research

Resumes

Resumes

Byron Kwan Photo 1

Senior Scientist

View page
Location:
1718 northwest 60Th St, Seattle, WA 98107
Industry:
Research
Work:
Seattle Genetics
Senior Scientist
Phase Diagnostics, Inc. Mar 2016 - Mar 2017
Director of Innovation
Nodus Therapeutics Mar 2016 - Mar 2017
Consultant
Massachusetts Institute of Technology (Mit) Oct 2010 - Feb 2016
Ph.d Candidate - Wittrup Lab
Ucla Apr 2008 - Jun 2010
Undergraduate Researcher - Kamei Lab
Education:
Massachusetts Institute of Technology 2010 - 2015
Doctorates, Doctor of Philosophy, Biological Engineering University of California, Los Angeles 2006 - 2010
Bachelors, Bachelor of Science, Bioengineering
Skills:
Cell Culture
Flow Cytometry
Matlab
Tumor Immunology
Fluorescence Microscopy
Western Blotting
Confocal Microscopy
Cancer Immunotherapy
Protein Engineering
Biological Engineering
Mouse Models
Pcr
Microsoft Office
Antibodies
Fplc
Cloning
Mouse Handling
Protein Expression
Protein Purification
Protein Production
Molecular Biology
Gel Electrophoresis
Immunohistochemistry
Immunofluorescence
Flowjo
Imagej
Graphpad Prism
Languages:
English

Publications

Us Patents

Synergistic Tumor Treatment With Il-2 And Integrin-Binding-Fc Fusion Protein

View page
US Patent:
20190343925, Nov 14, 2019
Filed:
Dec 21, 2018
Appl. No.:
16/230466
Inventors:
- Stanford CA, US
- Cambridge MA, US
Byron Hua KWAN - Seattle WA, US
International Classification:
A61K 38/20
A61K 47/64
A61K 39/395
A61K 38/38
A61K 38/16
C07K 16/40
C07K 16/30
A61K 38/17
A61K 45/06
C07K 14/55
C07K 16/22
C07K 16/28
C07K 16/24
Abstract:
The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.

Synergistic Tumor Treatment With Il-2, An Integrin-Binding-Fc Fusion Protein, And A Cancer Vaccine

View page
US Patent:
20190054145, Feb 21, 2019
Filed:
Feb 10, 2017
Appl. No.:
16/076597
Inventors:
- Cambridge MA, US
- Stanford CA, US
Cary Francis OPEL - Somerville MA, US
Kelly Dare MOYNIHAN - Allston MA, US
Jennifer R. COCHRAN - Stanford CA, US
Byron Hua KWAN - Seattle WA, US
International Classification:
A61K 38/20
A61K 39/395
A61K 39/00
A61K 47/60
A61K 47/68
A61K 47/64
A61P 35/00
Abstract:
The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.

Synergistic Tumor Treatment With Il-2 And Integrin-Binding-Fc-Fusion Protein

View page
US Patent:
20170216402, Aug 3, 2017
Filed:
Aug 12, 2015
Appl. No.:
15/501028
Inventors:
- Cambridge MA, US
- Palo Alto CA, US
Byron Hua KWAN - Boston MA, US
International Classification:
A61K 38/20
A61K 38/16
C07K 16/22
C07K 16/28
C07K 16/40
C07K 16/30
A61K 38/38
A61K 39/395
Abstract:
The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.

Synergistic Tumor Treatment With Extended-Pk Il-2 And Therapeutic Agents

View page
US Patent:
20150132254, May 14, 2015
Filed:
May 21, 2013
Appl. No.:
14/402889
Inventors:
- Cambridge MA, US
Byron Hua Kwan - Boston MA, US
Shuning Gai - Cambridge MA, US
International Classification:
A61K 38/20
A61K 45/06
A61K 47/48
A61K 39/395
A61K 38/38
US Classification:
424 852
Abstract:
The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
Control profile
Byron Hua Kwan from Seattle, WA, age ~37 Get Report